These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33043761)

  • 21. Case report of a complicated neurologically manifesting acute porphyria treated successfully with Givosiran.
    Steinberg T; Kilic M; Fuchs K; Hanyk K; Linker RA; Schlachetzki F; Neumann B
    J Neurol Sci; 2021 Mar; 422():117334. PubMed ID: 33581419
    [No Abstract]   [Full Text] [Related]  

  • 22. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
    Vassiliou D; Sardh E; Harper P; Simon AR; Clausen VA; Najafian N; Robbie GJ; Agarwal S
    Clin Pharmacol Ther; 2021 Nov; 110(5):1250-1260. PubMed ID: 34510420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
    Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK
    Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.
    Schmitt C; Lenglet H; Yu A; Delaby C; Benecke A; Lefebvre T; Letteron P; Paradis V; Wahlin S; Sandberg S; Harper P; Sardh E; Sandvik AK; Hov JR; Aarsand AK; Chiche L; Bazille C; Scoazec JY; To-Figueras J; Carrascal M; Abian J; Mirmiran A; Karim Z; Deybach JC; Puy H; Peoc'h K; Manceau H; Gouya L
    J Intern Med; 2018 Jul; 284(1):78-91. PubMed ID: 29498764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria].
    Stölzel U
    Z Gastroenterol; 2020 Aug; 58(8):785. PubMed ID: 32785915
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluating the Efficacy of a Small Interfering Ribonucleic Acid Molecule, Givosiran, in Treating Acute Intermittent Porphyria: A Systematic Review.
    Patel P; Midha S; Shukla S; Dhamija D; Bello AO; Khan S
    Cureus; 2023 Jun; 15(6):e40585. PubMed ID: 37469824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute intermittent porphyria, givosiran, and homocysteine.
    Fontanellas A; Ávila MA; Arranz E; Enríquez de Salamanca R; Morales-Conejo M
    J Inherit Metab Dis; 2021 Jul; 44(4):790-791. PubMed ID: 34145602
    [No Abstract]   [Full Text] [Related]  

  • 28. [Acute intermittent porphyria: Long-term follow up of 35 patients].
    Herrero C; Badenas C; Aguilera P; To-Figueras J
    Med Clin (Barc); 2015 Oct; 145(8):332-7. PubMed ID: 25194977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Penetrance and predictive value of genetic screening in acute porphyria.
    Baumann K; Kauppinen R
    Mol Genet Metab; 2020 May; 130(1):87-99. PubMed ID: 32067921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personalized dosage of Givosiran in acute intermittent porphyria.
    Garrido Montes M; Pertusa Mataix R; Garcia Morillo JS
    Med Clin (Barc); 2024 Sep; 163(5):260-261. PubMed ID: 38839445
    [No Abstract]   [Full Text] [Related]  

  • 31. Preventing hyperhomocysteinemia using vitamin B
    Redonnet-Vernhet I; Mercié P; Lebreton L; Blouin JM; Bronnimann D; Mesli S; Guibet C; Ribeiro E; Gensous N; Duffau P; Gouya L; Richard E
    Mol Genet Metab Rep; 2024 Jun; 39():101076. PubMed ID: 38601120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort.
    Lee MJ; Kuo HC; Chou LN; Sweetser MT; Wang JD
    J Formos Med Assoc; 2024 Jun; 123(6):679-686. PubMed ID: 38044204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Givosiran - Running RNA Interference to Fight Porphyria Attacks.
    Gonzalez-Aseguinolaza G
    N Engl J Med; 2020 Jun; 382(24):2366-2367. PubMed ID: 32521139
    [No Abstract]   [Full Text] [Related]  

  • 34. Givosiran: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Givosiran for the treatment of acute hepatic porphyria.
    Ricci A; Ventura P
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.
    Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL
    Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel treatment options for acute hepatic porphyrias.
    Wang B
    Curr Opin Gastroenterol; 2021 May; 37(3):194-199. PubMed ID: 33769375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute intermittent porphyria: Acute flare-up resolved with givosiran.
    Balado González AM; Feijoo-Massó C; Navarro-Saez MDC
    Med Clin (Barc); 2023 Nov; 161(10):454-455. PubMed ID: 37495504
    [No Abstract]   [Full Text] [Related]  

  • 39. Effectiveness and tolerability of givosiran for the management of acute hepatic porphyria: A monocenter real-life evaluation.
    Guida CC; Nardella M; Del Mar Ys Perez A; Savino M; Ferrara G; Napolitano F; Crisetti A; Aucella F; Aucella F
    Mol Genet Metab Rep; 2024 Sep; 40():101111. PubMed ID: 39027010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic strategies for acute intermittent porphyria.
    Zhao L; Wang X; Zhang X; Liu X; Ma N; Zhang Y; Zhang S
    Intractable Rare Dis Res; 2020 Nov; 9(4):205-216. PubMed ID: 33139979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.